Serial No.: 09/720,469

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claim 1. (Canceled).

Claim 2. (Currently Amended) An isolated tumor antigen peptide of 8-14 amino acids in length, which is a fragment of comprising an amino acid sequence that is a partial cyclophilin B sequence of SEQ ID NO:44, and that binds to an HLA antigen and is recognized by cytotoxic T lymphocytes.

Claim 3. (Canceled).

Claim 4. (Currently Amended) An isolated tumor antigen peptide of 8-14 amino acids in length comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-36 and SEQ ID NOs: 41-43, wherein the peptide binds to HLA antigen and is recognized by cytotoxic T lymphocytes.

Claims 5-7, (Canceled).

Serial No.: 09/720,469

Claim 8. (Currently Amended) An isolated tumor antiquen peptide The derivative of claim 6, in which the amino acid residue at position 2 in the amino acid sequence shown in any one of SEQ ID NOs: 1-11 is substituted by tyrosine, phenylalanine, methionine, or tryptophan, and/or the amino acid residue at the C-terminus is substituted by phenylalanine, leucine, isoleucine, tryptophan, or methionine.

Claim 9. (Canceled).

Claim 10. (Currently Amended) An isolated tumor antiquent peptide selected from the group consisting of The derivative of claim 8 comprising the amino acid sequence shown in SEQ ID NO: 37, or SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO:40.

Claim 11. (Canceled).

Claim 12. (Currently Amended) A composition comprising as an active ingredient at least one of substances selected from tumor antigen peptides and derivates thereof according to any one of claims 2, 4, 6, 8, or 10 or 11.

Claims 13-25. (Canceled).